KRAS mutations, particularly the KRAS-G12D substitution, have been shown to impair the tumor immune microenvironment (TIME) by reducing PD-L1 expression and chemokine secretion, which limits CD8+ T cell recruitment and promotes immunosuppression. This evidence concerns the gene KRAS and neoplasm.